Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2332652 | 0.93 | ALOX15 (0.35) | ALOX15 | |
| SCHEMBL9801033 | 0.88 | KEAP1 (0.32) | — | |
| SCHEMBL10560484 | 0.82 | — | — | |
| SCHEMBL29108978 | 0.81 | KEAP1 (0.33) | — | |
| SCHEMBL9286272 | 0.80 | PARP1 (0.33) | — | |
| SCHEMBL18963613 | 0.78 | — | — | |
| SCHEMBL4079651 | 0.78 | TSHR (0.31) | — | |
| SCHEMBL5953215 | 0.78 | — | — | |
| SCHEMBL990730 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL28025301 | 0.78 | PARP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108440734-A | A kind of polyurethane eyeglass and its short route curing | 上海伟星光学有限公司 | 2018-08-24 | — | — | CN | claimed |
| CN-110461897-A | Polyol component and use thereof for producing rigid polyurethane foams | BASF SE | 2019-11-15 | — | — | CN | disclosed |
| CN-110382583-A | Solvent-poor coating systems for textiles | 科思创德国股份有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-106459357-B | Aromatic nitrile-containing compositions for making transparent polythiourethane articles | 科思创德国股份有限公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-106573881-B | Method for producing xylylene diisocyanates in the gas phase | 科思创德国股份有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109642009-A | SILANE-FUNCTIONAL POLYMERIC POLYURETHANES | 科思创德国股份有限公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109422865-A | A kind of preparation method of polyurethane resin and its obtained polyurethane resin | 科思创德国股份有限公司 | 2019-03-05 | — | — | CN | disclosed |
| CN-105934437-B | Silane-modified formamide | 科思创德国股份有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-104144961-B | Hard polyurethane foams | 巴斯夫欧洲公司 | 2019-01-22 | — | — | CN | disclosed |
| CN-109153808-A | Fibre-reinforced foamed material | 巴斯夫欧洲公司 | 2019-01-04 | — | — | CN | disclosed |
| US-20150025059-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025059-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8883819-B2 | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension | IRM LLC (BM) | 2014-11-11 | — | — | US | disclosed |
| US-8883819-B2 | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension | IRM LLC (BM) | 2014-11-11 | — | — | US | disclosed |
| US-8883819-B2 | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension | IRM LLC (BM) | 2014-11-11 | — | — | US | disclosed |
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-12 | — | — | US | disclosed |
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-12 | — | — | US | disclosed |
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-12 | — | — | US | disclosed |
| WO-2013030802-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | PDGFA, PDGFRA, PDGFRB | ALOX15 3208/4885 |
| US-20150025059-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | PDGFA, PDGFRA, PDGFRB | ALOX15 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.